Proresolution Lipid Mediators in Multiple Sclerosis — Differential, Disease Severity-Dependent Synthesis — A Clinical Pilot Trial

Prüss, Harald; Rosche, Berit; Sullivan, Aaron B.; Brommer, Benedikt; Wengert, Oliver; Gronert, Karsten; Schwab, Jan M.
February 2013
PLoS ONE;Feb2013, Vol. 8 Issue 2, p1
Academic Journal
Background: The severity and longevity of inflammation is controlled by endogenous counter-regulatory signals. Among them are long-chain polyunsaturated fatty acid (PUFA)-derived lipid mediators, which promote the resolution of inflammation, an active process for returning to tissue homeostasis. Objective: To determine whether endogenous production of lipid-derived resolution agonists is regulated differentially in patients with highly active and less active multiple sclerosis (MS). Design: Matched-pairs study in University hospital Neurology department. Patients: Based on clinical (relapse frequency) and paraclinical (MRI lesions, contrast enhancement) criteria, 10 pairs of age- and sex-matched patients with relapsing-remitting MS were assigned either to a group with highly active or less active MS. Lipid mediators were quantified in serum and cerebrospinal fluid using LC-MS/MS-based lipidomics. Results: Levels of the key arachidonic (ω-6) and docosahexaenoic acid (ω-6)-derived mediators prostaglandins (PG), leukotrienes, hydroxyeicosatetraenoic acids (HETE) and resolution agonists lipoxin A4 (LXA4), resolvin D1 (RvD1) and neuroprotectin D1 (NPD1) were quantified. In the patient group with highly active MS, 15-HETE and PGE2 were increased, which are products of the 15-lipoxygenase and cyclooxygenase pathways. The proresolution mediator RvD1 was significantly upregulated and NPD1 was detected in the highly active group only. LXA4 levels were not increased in patients with highly active MS. Conclusions: Lipid mediator pathways are regulated differentially in the cerebrospinal fluid of MS patients, depending on disease severity. Non-exhaustive or possibly ‘delayed’ resolution pathways may suggest a defective resolution program in patients with highly active MS. Longitudinal analyses are required to hetero-typify this differential resolution capacity, which may be associated with disease progression, longevity and eventual termination.


Related Articles

  • Multiple sclerosis: therapeutic pessimism. Webb, H.E. // BMJ: British Medical Journal (International Edition);5/16/92, Vol. 304 Issue 6837, p1260 

    Examines the treatment of multiple sclerosis. Efficacy of cyclophosphamide and azathioprine; Impact of polyunsaturated fatty acids on patients with the disease; Correlations between fatty acids and myelin.

  • Trial of polyunsaturated fatty acids in non-relapsing multiple sclerosis. Bates, D.; Fawcett, P.R.W.; Shaw, D.A.; Weightman, D. // British Medical Journal;10/8/1977, Vol. 2 Issue 6092, p932 

    Examines the trial of polyunsaturated fatty acids in non-relapsing multiple sclerosis (MS). Findings on the relapses of the two-year trial; Observation on the clinical pattern of MS; Group of the clinical pattern of MS.

  • Modafinil for the treatment of multiple sclerosis-related fatigue.  // Current Medical Literature: Multiple Sclerosis;2010, Vol. 2 Issue 3, p82 

    In this article the author discusses the study "Modafinil for the Treatment of Multiple Sclerosis-related Fatigue." The study uses clinical trials which demonstrate the efficacy of modafinil compared with placebo-run phase as quantified by the self-reported Fatigue Severity Scale and Epworth...

  • No consequences of dietary n-3 polyunsaturated fatty acid deficiency on the severity of scopolamine-induced dry eye. Viau, Sabrina; Pasquis, Bruno; Maire, Marie-Annick; Fourgeux, Cynthia; Grégoire, Stéphane; Acar, Niyazi; Bretillon, Lionel; Creuzot-Garcher, Catherine; Joffre, Corinne // Graefe's Archive of Clinical & Experimental Ophthalmology;Apr2011, Vol. 249 Issue 4, p547 

    Purpose: Epidemiological studies suggest that dietary n-3 polyunsaturated fatty acids (PUFAs) may protect against dry eye. This study aimed to evaluate whether a dietary deficiency in n-3 PUFAs may increase the severity of the pathology in a scopolamine-induced model of dry eye in the rat....

  • Altered Colonic Mucosal Polyunsaturated Fatty Acid (PUFA) Derived Lipid Mediators in Ulcerative Colitis: New Insight into Relationship with Disease Activity and Pathophysiology. Masoodi, Mojgan; Pearl, Daniel S.; Eiden, Michael; Shute, Janis K.; Brown, James F.; Calder, Philip C.; Trebble, Timothy M. // PLoS ONE;Oct2013, Vol. 8 Issue 10, p1 

    Objectives: Ulcerative colitis (UC) is a relapsing inflammatory disorder of unconfirmed aetiology, variable severity and clinical course, characterised by progressive histological inflammation and with elevation of eicosanoids which have a known pathophysiological role in inflammation....

  • Polyunsaturated fatty acids in treatment of acute remitted multiple sclerosis. Bates, D.; Fawcett, P.R.W.; Shaw, D.A.; Weightman, D. // British Medical Journal;11/18/1978, Vol. 2 Issue 6149, p1390 

    Investigates the use of polyunsaturated fatty acids for the treatment of multiple sclerosis. Influence of linoleic acid on the severity of the disease; Correlation between multiple sclerosis and dietary fats; Evaluation of results in terms of clinical deterioration and severity of attacks.

  • Retinal inner nuclear layer volume reflects response to immunotherapy in multiple sclerosis. Knier, Benjamin; Schmidt, Paul; Aly, Lilian; Buck, Dorothea; Berthele, Achim; Mühlau, Mark; Zimmer, Claus; Hemmer, Bernhard; Korn, Thomas // Brain: A Journal of Neurology;Nov2016, Vol. 139 Issue 11, p2855 

    Assessment of inflammatory disease activity during multiple sclerosis is crucial for selecting appropriate disease-modifying therapies. Previous studies suggested that the retinal inner nuclear layer reflects inflammatory disease severity within the central nervous system. In our study,...

  • Chloroquine Treatment Enhances Regulatory T Cells and Reduces the Severity of Experimental Autoimmune Encephalomyelitis. Thomé, Rodolfo; Moraes, Adriel S.; Bombeiro, André Luis; Farias, Alessandro dos Santos; Francelin, Carolina; da Costa, Thiago Alves; Di Gangi, Rosária; dos Santos, Leonilda Maria Barbosa; de Oliveira, Alexandre Leite Rodrigues; Verinaud, Liana // PLoS ONE;Jun2013, Vol. 8 Issue 6, p1 

    Background: The modulation of inflammatory processes is a necessary step, mostly orchestrated by regulatory T (Treg) cells and suppressive Dendritic Cells (DCs), to prevent the development of deleterious responses and autoimmune diseases. Therapies that focused on adoptive transfer of Treg cells...

  • University of Illinois at Chicago Tests Diabetes Drug in Treatment of Multiple Sclerosis.  // Ascribe Newswire: Health;6/11/2004, p78 

    Researchers at the University of Illinois at Chicago are launching a clinical trial to determine whether a drug commonly used for diabetes might be effective in treating multiple sclerosis, an autoimmune disease that affects 350,000 Americans.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics